Brain Natriuretic Peptide Might Predict the Abnormal Geometry of Heart in Children with Chronic Kidney Disease
Authors:
J. Hedvig 1; Ľ. Podracká 1; D. Potočeková 2
Authors‘ workplace:
I. Klinika detí a dorastu LF UPJŠ a DFN, Košice
1; Ústav lekárskej informatiky LF UPJŠ, Košice
2
Published in:
Čas. Lék. čes. 2008; 147: 90-95
Category:
Original Article
Overview
Background.
Cardiovascular diseases are the leading course of morbidity/mortality in children with chronic kidney disease. Recently it has been shown that a brain natriuretic peptide is a sensitive cardiac marker for classification of the cardiovascular risk in adults. Whether it has the same diagnostic value in children with chronic kidney diseases has to be established. The purpose of the study was to evaluate whether the brain natriuretic peptide can predict cardiac dysfunction in children with chronic kidney disease.
Methods and Results.
Relation between serum level of the brain natriuretic peptide, echocardiography and cardiovascular risk factors (hypertension, anaemia, lipids, C-reactive protein, secondary hyperparathyreoidism) has been studied in 46 children (10 patients at predialysis, 14 patients on dialysis, 11 children with kidney transplant and 11 healthy controls). Brain natriuretic peptide was significantly higher in dialysed patients (2.09 ± 0.78) in comparison with healthy children (1.43 ± 0.34, p = 0.012) and with both groups of patients at pre-dialysis stage (1.52 ± 0.42, p = 0.039) and after kidney transplant (1.71 ± 0.46, p = 0.19). Abnormal heart geometry was found in 19 patients (54.28%). Compared to controls, brain natriuretic peptide was higher in children with eccentric but not in those with concentric hypertrophy (2.178 ± 0.956 vs. 1.496 ± 0.395, p = 0.05, resp. 1.982 ± 0.618 vs. 1.496 ± 0.395, p = 0.04). Significant correlation was found between levels of brain natriuretic peptide and ventricular hypertrophy (p = 0.00l), with the level of parathyroid hormone (p = 0.03) and with the degree of anaemia (p = 0.027).
Conclusions.
Brain natriuretic protein can predict an abnormal geometry of heart in children with chronic kidney disease. Our preliminary results suggest that it is a suitable marker of cardiovascular classification in paediatrics.
Key words:
brain natriuretic peptide, chronic kidney disease, left ventricular hypertrophy, cardiac geometry.
Sources
1. Mitsnefes, M. M.: Pediatric end–stage renal disease: heart as target. J. Pediatr., 2002, 141, s. 162–164.
2. Parekh, R. S, Caroll, C. E, Wolfe, R. A. et al.: Cardiovascular mortality in children and young adults with end–stage kidney disease. J. Pediatr., 2002, 141, s. 191–197.
3. Parfrey, P. S, Foley, R. N.: The clinical epidemiology of cardiac disease in chronic renal failure. J. Am. Soc. Nephrol., 1999, 10, s. 1606–1615.
4. Mitsnefes, M. M, Daniels, S. R, Schwartz, S. M et al.: Severe left ventricular hypertrophy in pediatric dialysis: Prevalence and predictors. Pediatr. Nephrol., 2000, 14, s. 898–902.
5. Longenecker, J. C., Coresh, J., Power, N. R. et al.: Traditional cardiovascular risk factors in dialysis patients compared with general population: The CHOICE study. J. Am. Soc. Nephrol., 2002, 13, s. 1918–1927.
6. Gruppen, M. P, Groothoff, J. W, Prins, M. et al.: Cardiac disease in young adults patients with end–stage renal disease since childhood: A Dutch cohort study. Kidney Int., 2003, 63, s. 1058–1065.
7. Sillberg, J. S, Barre, P. E, Prichard, S. S. et al.: Impact of left ventricular hypertrophy on survival in end–stage renal disease. Kidney Int.,1989, 36, s. 286–290.
8. Zoccali, C., Benedetto, F. A., Mallamaci, F. et al.: Left ventricular mass monitoring in the follow–up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int., 2004, 65, s. 1492–1498.
9. Levy, D., Garrison, R. J., Savage, D. D. et al.: Prognostic implications of echocardiographically determined left ventricular mass in Framingham Heart Study. N. Eng. J. Med., 1990, 322, s. 1561–1566.
10. Matteucci, M. C., Wühl, E., Picca, S. et al.: Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J. Am. Soc. Nephrol., 2006, 17, s. 218–226.
11. Members of the Chamber Quantification Writing Group are: Lang, R. M., Bierig, M., Devereux, R. B. et al: Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr., 2005, 18, s. 1440–1460.
12. Daniels, S. R., Kimball, T. R., Morrison, J. A. et al.: Indexing left ventricular mass to account for differencies in body size in children and adolescents without cardiovascular disease. Am. J. Cardiol., 1995, 76, s. 699–701.
13. Urbina, E. M., Gidding, S. S., Bao, W. et al.: Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. Circulation, 1995, 91, s. 2400–2406.
14. de Simone, G., Kizer, J., Chinali, M. et al.: Normalisation for body size and population attributable risk of left ventricular hypertrophy: The Strong Heart Study. Am. J. Hypertens., 2005, 18, s. 191–196.
15. Mitsnefes, M. M., Kimball, T. R., Witt, S. A. et al.: Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation, 2003, 107, s. 864–868.
16. Mitsnefes, M. M, Kimball, T. R., Border, W. L. et al.: Impaired left ventricular diastolic function in children with chronic renal failure. Kidney Int., 2004, 65, s. 1461–1466.
17. Grossman, W., Jones, D., McLaurin, L. P.: Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest., 1975, 56, s. 56–64.
18. Cataliotti, A., Malatino, L., Jougasaki, M. et al.: Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clinic Proc., 2001, 76, s. 1111–1119.
19. Clerico, A., Capriolo, R., Del Ry, S. et al.: Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J. Endocrinol. Invest., 2001, 24, s. 24–30.
20. Blacher, J., Guerin, A. P., Pannier, B. et al.: Arterial calcifications, arterial stiffness, and cardiovascular risk in end–stage renal disease. Hypertension, 2001, 38, s. 938–942.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- The Occurrence of Malignancies in Former Blood Donors
- Complications with the Pocket of Cardiostimulator
- Tracheal Intubation without Muscle Relaxant – the Impact of Different Sufentanil Doses on the Quality of Intubating Conditions: A Prospective Study
- Is the Extent of Present Examination of Blood Donors Sufficient? Malignancies in Active Blood Donors